



July 12, 2021

To,

Manager (CDR)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, Dalal Street,
Mumbai-400001.

Ref: DR LALCHANDANI LABS LIMITED (Scrip Code: 541299)

Subject: Outcome of the Board Meeting dated 12.07.2021.

Dear Sir/ Madam,

With reference to the above cited subject, we would like to inform you that Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 we are enclosing herewith;

1. Statement showing the Audited Financial Statement Result for the half year and year ended March 31, 2021 along with Auditors Report on Audited Financial Results is also enclosed herewith, and
2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May, 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended March 31, 2021, is also enclosed herewith.

The Said meeting of the Board of Directors commenced at 04.00.pm and concluded at 6.45 pm.

Please take the same on your record.

Thanking You,


Yours Faithfully,

For DR LALCHANDANI LABS LIMITED



Arjan Lalchandani
Managing Director
DIN: 07014579

Encl: As Above



DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniopathlab.com>, Email id: info@lalchandaniopathlab.com

Phone: 8010689689/ 8010998844

AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2021*Amount Rs. in Lakhs*

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2021	30.09.2020	31.03.2020	31.03.2021	31.03.2020
		Audited	Un-audited	Audited	Audited	Audited
I	Revenue from Operations	706.69	271.30	306.96	978.00	610.39
II	Other Income		-		-	-
III	Total Revenue (I+II)	706.69	271.30	306.96	978.00	610.39
IV	Expenses					
	(a) Cost of materials consumed	256.49	104.10	63.42	360.59	114.62
	(b) Employee benefits expense	38.55	31.82	41.94	70.37	86.21
	(c) Finance Cost	30.11	5.27	9.29	35.38	18.50
	(d) Depreciation and amortisation expense	28.70	22.82	21.76	51.53	42.30
	(e) Other Expenses	244.35	78.05	147.58	322.39	282.68
	Total Expenses	598.21	242.05	283.99	840.26	544.30
V	Profit before exceptional and extraordinary items and tax (III - IV)	108.48	29.25	22.97	137.74	66.08
VI	Exceptional Items					
VII	Profit-extraordinary items and tax (V - VI)	108.48	29.25	22.97	137.74	66.08
VIII	Extraordinary Items					
IX	Profit before tax (VIII - IX)	108.48	29.25	22.97	137.74	66.08
X	Tax Expenses:					
	(1) Current Tax	24.60	6.69	8.92	31.29	15.81
	(2) Deferred Tax	5.31	-	2.78	5.31	2.84
XI	Profit / (Loss) from period from continuing operations (VII - VIII)	78.57	22.56	11.28	101.13	47.43
XII	Profit (Loss) from discontinuing Operations	-	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-	-

XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	78.57	22.56	11.28	101.13	47.43
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	1.81	0.52	0.78	2.33	1.09
	(b) Diluted (Rs.)	1.81	0.52	0.78	2.33	1.09

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 12th July 2021.
2. The Company runs laboratories for carrying out pathological investigations.
3. There were no investor complaints received / pending as at 31st March, 2021
4. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
5. As per AS 20 Earnings Per Share (EPS) issued by ICAI weighted average number of equity shares are used as the denominator in calculating basic and diluted earnings per share giving effect to Right Issue, Bonus Issue and Initial Public Offer.
6. The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19, The Company has taken into account the possible impact of COVID-19 in preparation of the audited standalone financial results, including its assessment of recoverable value of its assets based on internal and external information up to the date of approval of these audited standalone financial results and current indicators of future economic conditions.

The Company is authorized by ICMR to perform COVID-19 tests using RT-PCR technology.

7. Previous year's figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period.

For Dr Lalchandani Labs Limited,



Dr. Arjan Lalchandani
Managing Director
(DIN: 07014579)

New Delhi

12-July-2021

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048

Website: <http://lalchandaniplab.com>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 31.03.2021

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended	
		31.03.2021	31.03.2020
1	Shareholders' Funds		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	521.89	420.76
	(c) Money received against share warrants	-	-
	Sub-total-Shareholders' Funds	955.20	854.07
2	Share application money pending allotment		
3	Non Current Liabilities		
	(a) Long Term Borrowings	264.09	170.85
	(b) Deferred Tax Liability	13.32	8.01
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-total-Non Current Liabilities	277.40	178.86
4	Current Liabilities		
	(a) Short Term Borrowings	139.73	5.01
	(b) Trade Payables		
	(i) Total Outstanding dues of micro enterprises and small enterprises	41.56	10.06
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	54.59	102.30
	(c) Other Current Liabilities	20.05	27.31
	(d) Short Term Provisions	31.29	15.81
	Sub-total-Current Liabilities	287.23	160.49
	TOTAL EQUITY AND LIABILITIES	1,519.83	1,193.42
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	473.00	331.63
	(ii) Intangible assets	51.35	15.49
	(b) Non Current Investments	24.10	24.10

	(c) Long Term Loans & Advances	92.02	31.75
	(d) Other Non Current Assets	22.87	34.30
	Sub-total-Non Current Assets	663.34	437.26
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	67.70	49.70
	(c) Trade Receivables	399.22	332.75
	(d) Cash & cash equivalents	289.24	225.28
	(e) Short Term Loans & Advances	43.00	106.17
	(f) Other Current Assets	57.33	42.26
	Sub-total-Current Assets	856.48	756.16
	TOTAL ASSETS	1,519.83	1,193.42

For Dr Lalchandani Labs Limited,



Dr. Arjan Lalchandani
Managing Director
(DIN: 07014579)

New Delhi
12-July-2021

DR LALCHANDANI LABS LIMITED

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048

Website: <http://lalchandaniplab.com>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

Cash Flow Statement for the Year Ended 31.03.2021			
	Particulars	F.Y.2020-21	F.Y.2019-20
		Amount	Amount
A	Cash Flow from Operating Activities		
	Net Profit/(Loss) Before Tax	137.74	66.08
	Adjustment For:		
	Depreciation	51.53	42.30
	Interest Expense	17.93	9.15
	<u>Operating Profit Before Working Capital Changes</u>	207.19	117.53
	<u>Changes in Working Capital</u>		
	Change in Sundry Debtors	(66.47)	(152.05)
	Change in Other Current Assets & Non-Current Assets	(3.64)	22.75
	Change in Trade Payables	(16.21)	47.76
	Changes in Inventories	(17.99)	(10.50)
	Change in Other Current Liabilities	8.22	(0.79)
	Direct Taxes Paid	(31.29)	(15.77)
		(127.38)	(108.59)
	Net Cash Flows from Operating Activities(A)	79.81	8.95
B	Cash Flow from Investing Activities		
	Purchase of Fixed Assets	(228.77)	(61.39)
	Loans and Advances given	2.90	(0.93)
	Net Cash Flow from Investing Activities (B)	(225.87)	(62.32)
C	Cash Flow from Financing Activities		
	Long Term Borrowings taken	93.23	85.40
	Short Term Borrowings	134.73	
	Interest Paid	(17.93)	(9.15)
	Net Cash Flow From Financing Activities (C)	210.03	76.25

	<u>Net Change in Cash (A+B+C)</u>	63.97	22.87
	Cash and Cash Equivalents at the Beginning of Year	225.28	202.40
	Cash and Cash Equivalents at the End of Year	289.24	225.28

For Dr Lalchandani Labs Limited,



Dr. Arjan Lalchandani
Managing Director
(DIN: 07014579)

New Delhi
12-July-2021



Jain Agarwal & Company

Chartered Accountants

Independent Auditor's report on Audited Half Yearly financial results and year to date results of the company pursuant to the regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

TO

THE BOARD OF DIRECTORS OF
DR LALCHANDANI LABS LIMITED

We have audited the accompanying half yearly and year to date financial results of **Dr Lalchandani Labs Limited** ("the company") which includes joint operations for the half year ended and year ended 31st March, 2021 ("the statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Our opinion is qualified for

Gratuity Liability & Leave Encashment Liability is not provided for in the books of accounts of the company and is thus not in accordance with Accounting Standard 15 on "Employee Benefits" issued by the Institute of Chartered Accountants of India.

Subject to above

In our opinion and to the best of our information and according to the explanations given to us these financial results: -

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the accounting standards and other accounting principles generally accepted in India of the net profit/loss and other financial information for the half year and year ended 31st March, 2021.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act).

Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

Amount receivables, Amount payables, Loans & Advances to various parties are subject to confirmation and reconciliation.

Our opinion is not modified in respect of these matters.



Covid-19 has put significant accounting and auditing challenges due to the Government's restrictions imposed during the lockdown for safety concerns. We have performed alternate audit procedures based on documents and information made available and relied upon by us.

Covid Impact — In view of the highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent on the circumstances, as they evolve.

Management's Responsibility for the Financial Statements

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance "with Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance "with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate to modify our opinion. Our Conclusion are based on the audit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The statement includes the results for the half year ended March 31, 2021 being the balancing figure between the audited figures in respect of the full year ended March 31, 2021 and published unaudited half year of the current financial year, which were subject to limited review by us, as required under the listing regulations.

For and on behalf of
Jain Agarwal and Company
Firm's Registration No: 024866N



CA Karan Jain
(Partner)
Membership No. – 521992
UDIN: 21521992AAAACQ8480

Place: New Delhi
Date: July 12, 2021.



Date: July 12, 2021

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Ref: Dr Lalchandani Labs Limited (Scrip Code – 541299)

Subject- Declaration of Audit Report with Unmodified Opinion pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir/ Madam,

We hereby declare that Jain Agarwal & Company, Chartered Accountant (Firm's Registration No. 024866N), Statutory Auditors of the Company, have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2021.

The declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/ LAD-NRO/GN/2016-17/001 dated May 25, 2016 and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

This is for your information and records.

Thanking you,

For **Dr Lalchandani Labs Limited**



Arjan Lalchandani
Managing Director
DIN: 07014579

